Journal of Clinical Oncology
Articles in this Issue
The frequency of driver mutations in non-small cell lung cancer patients: The Turkish nation-wide, observational, Registurk-Lung study (updated analysis).
e20501 Background: The role of biomarkers in the treatment of non-small cell lung cancer is increasing. Biomarker evaluation is performed in almost all of...
A phase 2 study to determine the clinical and pathological (path) response to neoadjuvant nivolumab (nivo) and relatlimab (rela) in stage II to IV (M0) resectable cutaneous squamous cell carcinoma (Neo-SCC).
TPS9610 Background: Cutaneous squamous cell carcinoma (cuSCC) is the second most common skin cancer worldwide (Bray et al. 2018). While 90% of cases are c...
Integrated CTC- and EV-based detection of PSMA protein and efficacy of <sup>177</sup> Lu-PSMA-617 radioligand therapy.
5083 Background: Blood-based predictive biomarkers of sensitivity to 177 Lu-PSMA-617 are lacking, and may facilitate clinical deci...
AZUR-4, a phase 2, open label, randomized study of neoadjuvant dostarlimab plus capecitabine plus oxaliplatin (CAPEOX) versus CAPEOX alone in previously untreated T4N0 or stage III mismatch repair proficient/microsatellite stable resectable colon cancer.
TPS3649 Background: Colon cancer is the third most common cancer globally, with a standard of care in the nonmetastatic setting that includes surgery foll...
Assessing the impact of financial toxicity among cancer patients on immunotherapy and targeted therapy: Insights from a tertiary cancer centre in south India.
e13530 Background: Cancer is currently the second leading cause of death globally – a burden disproportionately borne by low- and middle-income countries,...
Clinical features and outcomes in Hispanic/Latino (HL) with metastatic renal cell carcinoma (mRCC) treated with systemic therapy.
e16525 Background: RCC has a rising worldwide incidence. Data on clinical features and outcomes in the HLs with mRCC are limited. This is a retrospective...
Regional disability-adjusted life years (DALYs) and mortality rates in gastric cancer among elderly (70+ years) from 1990-2021: A global burden of disease study.
e16076 Background: Gastric cancer is the fourth leading cause of global cancer deaths. Despite declining incidence and mortality, it remains a significant...
Patient-reported quality of life and symptoms in children treated with chimeric antigen receptor (CAR) T cell therapy: A prospective cohort study.
e22021 Background: Chimeric Antigen Receptor (CAR) T cell therapy is a standard therapy for relapsed Acute Lymphoblastic Leukemia (ALL) and remains an imp...
Preliminary deep learning model to predict residual tumor in advanced epithelial ovarian cancer.
e13701 Background: The optimal therapeutic strategy for advanced epithelial ovarian cancer (EOC) — primary debulking surgery (PDS) followed by adjuvant ch...
Effect of post-discharge symptom monitoring on hospital readmissions: A randomized trial.
1514 Background: There is growing interest to improve patient care transitions from hospital to home and to prevent readmissions but effective interventio...
TACE combined with the intra-arterial infusion of bevacizumab for BCLC-stage B hepatocellular carcinoma beyond up-to-seven criteria: A prospective, single-arm, phase II study.
e16302 Background: TACE is recommended as the standard of care for patients with BCLC-B stage hepatocellular carcinoma (HCC). However, the BCLC-B stage HC...
Influence of inhaled corticosteroids on immune checkpoint inhibitor pneumonitis and mortality in patients with COPD and lung cancer.
e20628 Background: The use of inhaled corticosteroids (ICS) in patients with chronic obstructive pulmonary disease (COPD) requires careful clinical judgme...
Development of a pediatric oncology financial toxicity outcome measure with content and face validity: The Parent-Reported Instrument of Costs and Experiences with financial toxicity (PRICE) measure.
10073 Background: Cancer treatment often leads to adverse financial consequences for patients and families (i.e., financial toxicity, FT). There is no val...
Neotrace: A multicenter phase II study of neoadjuvant sacituzumab govitecan plus zimberelimab followed by adjuvant zimberelimab with or without sacituzumab govitecan in patients with resectable non-small cell lung cancer.
TPS8120 Background: Phase III trials, including KEYNOTE-671, have established combined neoadjuvant chemoimmunotherapy followed by adjuvant immunotherapy (...
Efficacy of subsequent treatment after combination therapy in non-clear cell renal cell carcinoma (nccRCC).
4545 Background: The treatment landscape of front-line nccRCC has evolved with recent trials demonstrating the efficacy of combination systemic therapy. H...
PD-L1 as a biomarker in gastric cancer: Concordance between IHC methods.
e15075 Background: The programmed cell death protein 1 ligand (PD-L1) has emerged as a biomarker that determines the progression and prognosis of gastric...
A multicenter prospective study to evaluate the efficacy of resection for initially unresectable hepatocellular carcinoma after atezolizumab combined with bevacizumab (the RACB study).
e16193 Background: The IMbrave150 study demonstrated that atezolizumab plus bevacizumab (atezo+bev) is superior to sorafenib in terms of progression-free...
Real world outcomes for patients with metastatic castration resistant prostate cancer (mCRPC) and <i>AR</i> T878A alterations treated with enzalutamide.
5053 Background: Androgen receptor (AR) antagonists such as enzalutamide (enza) are standard therapy for mCRPC. AR alterations suc...
An open-label, phase Ib dose-expansion study to assess the efficacy of CD137/FAP agonist BI 765179 plus pembrolizumab as a first-line treatment in metastatic or incurable, recurrent programmed cell death ligand-1 (PD-L1)-positive head and neck squamous cell carcinoma (HNSCC).
TPS2684 Background: HNSCC is the seventh most common cancer globally and is often associated with poor quality of life and a dismal prognosis. Median over...
Disparities in outcomes of metastatic prostate cancer hospitalizations: 2008-2021.
e13836 Background: Despite initial responses to therapy, metastatic prostate cancer remains a progressive and lethal disease that is associated with poor...
A multisite randomized trial of an advanced pneumatic compression device vs usual care for head and neck cancer related lymphedema: Short-term results.
6107 Background: Lymphedema is common in head and neck cancer survivors (HNCS). Published data indicate that an Advanced Pneumatic Compression Device (APC...
Phase I study of hV01, a recombinant human IL-21-expressing oncolytic vaccinia virus, as monotherapy in advanced solid tumors.
2570 Background: Oncolytic viruses have shown an excellent safety profile and can initiate antitumour immunity through in-situ tumor lysis and systemic im...
Where you live and who you are: The unequal face of cancer and diabetes mortality in the United States.
e22556 Background: Cancer and diabetes represent leading causes of mortality in the United States, with considerable disparities in rates across demograph...
Hypoxia-inducible factor-2α (HIF-2α) inhibitor belzutifan in von Hippel-Lindau (VHL) disease–associated neoplasms: 5-year follow-up of the phase 2 LITESPARK-004 study.
4507 Background: The HIF-2α inhibitor belzutifan is approved for the treatment of patients with VHL disease–associated renal cell carcinoma (RCC), CNS hem...
Progesterone receptor expression and survival outcomes in metastatic breast cancer: A retrospective analysis of CDK4/6 inhibitor–treated patients in a tertiary care center.
e13069 Background: Progesterone receptor (PR) status significantly impacts breast cancer prognosis, yet its role in Mexican metastatic breast cancer (MBC)...